
Opinion|Videos|May 26, 2025
Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
Panelists discuss how proactive patient education, lipid-lowering interventions, and monitoring tools can help patients stay on ALK inhibitor therapy to realize long-term benefits.
Advertisement
Episodes in this series

ALK Inhibitor Therapy Management
Main Discussion Topics
- Patient education strategies for lorlatinib therapy adherence
- Lipid-lowering interventions to support long-term lorlatinib treatment
- Monitoring tools for patients on ALK inhibitors
- Patient education methodologies specific to ALK inhibitor therapy
Discussion Questions Posed
- Grizzard inquired about proactive patient education and lipid-lowering interventions to help patients maintain lorlatinib therapy for long-term benefits
Castronovo asked about potentially useful tools for educating and monitoring patients on ALK inhibitors
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
Medicaid Pays for Half of All Pediatric Hospitalizations
3
Guselkumab Shows Sustained 48-Week Protection Against Joint Damage in PsA
4
Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch
5














































